Late cyclosporine treatment ameliorates established coronary graft disease in rat allografts

Nobuhiro Handa, Masataka Hatanaka, William A Baumgartner, Bruce A. Reitz, Gordon Sandford, Ahmed H. Esa, Ahvie Herskowitz

Research output: Contribution to journalArticle

Abstract

The development of post-transplantation coronary graft disease (CGD) is a major cause of late morbidity and mortality. Recent reports have suggested that CGD is a type of chronic vascular rejection, possibly enhanced by cofactors such as concurrent CMV infection and hyperlipidemia. It remains controversial whether established CGD can be improved by modifications in immunosuppressive therapy. The purpose of this study was to examine whether CsA could reverse or halt the progression of CGD after it was already established. Lewis to Fisher (F-344) heterotopic heart allografts develop CGD resembling human disease. Group 1 (n=29) had no CsA therapy for chronic rat CMV (RCMV) infection in recipients for 8 weeks before transplant. Group 2 (n=17) had chronic RCMV infection along with CsA therapy from days 15 to 28 post-transplant. Allografts were killed at 2 and 4 weeks and 90 days post-transplantation. In group 1, leukocyte adhesion to arterial endothelium and intimal hyperplasia were well established at 2 weeks and progressed to stenotic, proliferative arterial lesions at 4 weeks. In group 2, CsA therapy was effective in significantly reversing histologic parameters of vascular rejection such as leukocyte adhesion, intimal proliferation, and periarterial edema at 4 weeks. By 90 days, however, arterial pathology was as severe as in group 1. In conclusion, these results support the hypothesis that CGD is a form of chronic vascular rejection, and once established, can be significantly modified by CsA therapy. These effects are not permanent, and progressive CGD recurs after CsA therapy is discontinued.

Original languageEnglish (US)
Pages (from-to)535-540
Number of pages6
JournalTransplantation
Volume56
Issue number3
StatePublished - 1993

Fingerprint

Cyclosporine
Allografts
Coronary Disease
Transplants
Tunica Intima
Blood Vessels
Leukocytes
Therapeutics
Infection
Transplantation
Immunosuppressive Agents
Hyperlipidemias
Endothelium
Hyperplasia
Edema
Pathology
Morbidity
Mortality

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Handa, N., Hatanaka, M., Baumgartner, W. A., Reitz, B. A., Sandford, G., Esa, A. H., & Herskowitz, A. (1993). Late cyclosporine treatment ameliorates established coronary graft disease in rat allografts. Transplantation, 56(3), 535-540.

Late cyclosporine treatment ameliorates established coronary graft disease in rat allografts. / Handa, Nobuhiro; Hatanaka, Masataka; Baumgartner, William A; Reitz, Bruce A.; Sandford, Gordon; Esa, Ahmed H.; Herskowitz, Ahvie.

In: Transplantation, Vol. 56, No. 3, 1993, p. 535-540.

Research output: Contribution to journalArticle

Handa, N, Hatanaka, M, Baumgartner, WA, Reitz, BA, Sandford, G, Esa, AH & Herskowitz, A 1993, 'Late cyclosporine treatment ameliorates established coronary graft disease in rat allografts', Transplantation, vol. 56, no. 3, pp. 535-540.
Handa, Nobuhiro ; Hatanaka, Masataka ; Baumgartner, William A ; Reitz, Bruce A. ; Sandford, Gordon ; Esa, Ahmed H. ; Herskowitz, Ahvie. / Late cyclosporine treatment ameliorates established coronary graft disease in rat allografts. In: Transplantation. 1993 ; Vol. 56, No. 3. pp. 535-540.
@article{c0b84e80cb3047e7831e029f8f3c4576,
title = "Late cyclosporine treatment ameliorates established coronary graft disease in rat allografts",
abstract = "The development of post-transplantation coronary graft disease (CGD) is a major cause of late morbidity and mortality. Recent reports have suggested that CGD is a type of chronic vascular rejection, possibly enhanced by cofactors such as concurrent CMV infection and hyperlipidemia. It remains controversial whether established CGD can be improved by modifications in immunosuppressive therapy. The purpose of this study was to examine whether CsA could reverse or halt the progression of CGD after it was already established. Lewis to Fisher (F-344) heterotopic heart allografts develop CGD resembling human disease. Group 1 (n=29) had no CsA therapy for chronic rat CMV (RCMV) infection in recipients for 8 weeks before transplant. Group 2 (n=17) had chronic RCMV infection along with CsA therapy from days 15 to 28 post-transplant. Allografts were killed at 2 and 4 weeks and 90 days post-transplantation. In group 1, leukocyte adhesion to arterial endothelium and intimal hyperplasia were well established at 2 weeks and progressed to stenotic, proliferative arterial lesions at 4 weeks. In group 2, CsA therapy was effective in significantly reversing histologic parameters of vascular rejection such as leukocyte adhesion, intimal proliferation, and periarterial edema at 4 weeks. By 90 days, however, arterial pathology was as severe as in group 1. In conclusion, these results support the hypothesis that CGD is a form of chronic vascular rejection, and once established, can be significantly modified by CsA therapy. These effects are not permanent, and progressive CGD recurs after CsA therapy is discontinued.",
author = "Nobuhiro Handa and Masataka Hatanaka and Baumgartner, {William A} and Reitz, {Bruce A.} and Gordon Sandford and Esa, {Ahmed H.} and Ahvie Herskowitz",
year = "1993",
language = "English (US)",
volume = "56",
pages = "535--540",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Late cyclosporine treatment ameliorates established coronary graft disease in rat allografts

AU - Handa, Nobuhiro

AU - Hatanaka, Masataka

AU - Baumgartner, William A

AU - Reitz, Bruce A.

AU - Sandford, Gordon

AU - Esa, Ahmed H.

AU - Herskowitz, Ahvie

PY - 1993

Y1 - 1993

N2 - The development of post-transplantation coronary graft disease (CGD) is a major cause of late morbidity and mortality. Recent reports have suggested that CGD is a type of chronic vascular rejection, possibly enhanced by cofactors such as concurrent CMV infection and hyperlipidemia. It remains controversial whether established CGD can be improved by modifications in immunosuppressive therapy. The purpose of this study was to examine whether CsA could reverse or halt the progression of CGD after it was already established. Lewis to Fisher (F-344) heterotopic heart allografts develop CGD resembling human disease. Group 1 (n=29) had no CsA therapy for chronic rat CMV (RCMV) infection in recipients for 8 weeks before transplant. Group 2 (n=17) had chronic RCMV infection along with CsA therapy from days 15 to 28 post-transplant. Allografts were killed at 2 and 4 weeks and 90 days post-transplantation. In group 1, leukocyte adhesion to arterial endothelium and intimal hyperplasia were well established at 2 weeks and progressed to stenotic, proliferative arterial lesions at 4 weeks. In group 2, CsA therapy was effective in significantly reversing histologic parameters of vascular rejection such as leukocyte adhesion, intimal proliferation, and periarterial edema at 4 weeks. By 90 days, however, arterial pathology was as severe as in group 1. In conclusion, these results support the hypothesis that CGD is a form of chronic vascular rejection, and once established, can be significantly modified by CsA therapy. These effects are not permanent, and progressive CGD recurs after CsA therapy is discontinued.

AB - The development of post-transplantation coronary graft disease (CGD) is a major cause of late morbidity and mortality. Recent reports have suggested that CGD is a type of chronic vascular rejection, possibly enhanced by cofactors such as concurrent CMV infection and hyperlipidemia. It remains controversial whether established CGD can be improved by modifications in immunosuppressive therapy. The purpose of this study was to examine whether CsA could reverse or halt the progression of CGD after it was already established. Lewis to Fisher (F-344) heterotopic heart allografts develop CGD resembling human disease. Group 1 (n=29) had no CsA therapy for chronic rat CMV (RCMV) infection in recipients for 8 weeks before transplant. Group 2 (n=17) had chronic RCMV infection along with CsA therapy from days 15 to 28 post-transplant. Allografts were killed at 2 and 4 weeks and 90 days post-transplantation. In group 1, leukocyte adhesion to arterial endothelium and intimal hyperplasia were well established at 2 weeks and progressed to stenotic, proliferative arterial lesions at 4 weeks. In group 2, CsA therapy was effective in significantly reversing histologic parameters of vascular rejection such as leukocyte adhesion, intimal proliferation, and periarterial edema at 4 weeks. By 90 days, however, arterial pathology was as severe as in group 1. In conclusion, these results support the hypothesis that CGD is a form of chronic vascular rejection, and once established, can be significantly modified by CsA therapy. These effects are not permanent, and progressive CGD recurs after CsA therapy is discontinued.

UR - http://www.scopus.com/inward/record.url?scp=0027386206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027386206&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 535

EP - 540

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 3

ER -